Shattuck Labs initiates a public offering of common stock or pre-funded warrants to certain investors, without disclosing the offering size.
Shattuck Labs Inc (STTK) has launched a public offering of its common stock. Certain investors may receive pre-funded warrants to purchase common stock instead of shares directly. The company has not yet disclosed the size or terms of the offering.
The move follows recent capital-raising efforts by biotech firms amid volatile market conditions. Shattuck Labs, focused on oncology and immunology therapies, last reported cash reserves of $185.4 million as of March 31, 2024. No prior public offering of common stock has been conducted by the company.
Market reaction to the announcement was not immediately available.